BASAGLAR (Eli Lilly and Company)
Welcome to the PulseAid listing for the BASAGLAR drug offered from Eli Lilly and Company. This Insulin [Chemical/Ingredient],Insulin Analog [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Eli Lilly and Company |
NON-PROPRIETARY NAME: | Insulin glargine |
SUBSTANCE NAME: | INSULIN GLARGINE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Insulin [Chemical/Ingredient],Insulin Analog [EPC] |
ROUTE: | SUBCUTANEOUS |
DOSAGE FORM: | INJECTION, SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2015-12-16 |
END MARKETING DATE: | 0000-00-00 |
BASAGLAR HUMAN PRESCRIPTION DRUG Details:
Item Description | BASAGLAR from Eli Lilly and Company |
LABELER NAME: | Eli Lilly and Company |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 100([iU]/mL) |
START MARKETING DATE: | 2015-12-16 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0002-7715_f28edb9a-75bd-4005-8c65-eefc64770124 |
PRODUCT NDC: | 0002-7715 |
APPLICATION NUMBER: | NDA205692 |
Other INSULIN GLARGINE Pharmaceutical Manufacturers / Labelers: